Intravesical therapy for bladder cancer: now and future
نویسندگان
چکیده
منابع مشابه
Intravesical Therapy for Superficial Bladder Cancer
The intravesical instillation of therapeutic agents for the treatment of localized bladder cancer began in 1903 when Herring[1] summarized his experience with silver nitrate. Since then, intravesical chemotherapy and immunotherapy have emerged as effective adjuncts to endoscopic resection for superficial transitional cell carcinoma of the bladder. Although advances in the treatment of superfici...
متن کاملIntravesical Therapy for Superficial Bladder Cancer
Transitional cell carcinoma of the bladder remains a significant health problem in the United States. Approximately 54,400 new cases of transitional cell carcinoma were reported in the United States in 1999, and an estimated 12,500 deaths were attributed to this cancer.[1] These statistics have remained relatively unchanged over the last several decades despite improvements in both diagnostic i...
متن کاملIntravesical therapy in superficial bladder cancer.
OBJECTIVE To identify the appropriate characteristics of superficial bladder cancer that allow the physician to predict tumor behavior. METHODS We analyzed 1,745 patients with primary superficial bladder cancer with regard to disease and patient characteristics. RESULTS With the characteristics we found, the population can be described and prognostic factors can be found. Moreover, with the...
متن کاملPaclitaxel-loaded gelatin nanoparticles for intravesical bladder cancer therapy.
PURPOSE The present report describes the development of paclitaxel-loaded gelatin nanoparticles for use in intravesical therapy of superficial bladder cancer. The commercial formulation of paclitaxel contains Cremophor, which forms micelles and thereby entraps the drug and reduces its partition across the urothelium. EXPERIMENTAL DESIGN Paclitaxel-loaded gelatin nanoparticles were prepared us...
متن کاملDevelopments in intravesical therapy for non-muscle-invasive bladder cancer.
Non-muscle-invasive bladder cancer is a frequent and heterogeneous disease with varying oncologic outcomes. The main goal in treating is to prevent recurrences and progression to muscle-invasive disease. Developments to improve the quality of transurethral resection of the bladder tumor and new chemotherapeutic options, including two device-assisted therapies, are being discussed. A problem is ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Drug Delivery System
سال: 2006
ISSN: 0913-5006,1881-2732
DOI: 10.2745/dds.21.46